arrow
C

C. Willemien Menke-van der Houven van Oordt

department of medical oncology
H指数:31
被引数:3,463

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer
2026-07-060
OA
Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast Cancer

循环肿瘤细胞通过活检或FES-PET评估之外增强内分泌治疗转移性乳腺癌的预后分层

2026-04-170
OA
89Zr-mAb uptake interpretation requires the use of tissue to plasma ratios corrected for antibody catabolism

89Zr-mAb的摄取解释需要使用校正了抗体分解代谢的组织与血浆比率。

2025-09-260
OA
Comparative analysis of FES-PET/CT and FDG-PET/CT in patients with ER-positive metastatic invasive lobular breast cancer

FES-PET/CT与FDG-PET/CT在ER阳性转移性浸润性小叶乳腺癌患者中的比较分析

2025-09-130
PREAI
The Diagnostic Accuracy of 18F-FDG PET and 18F-FES PET for Staging Grade 1-2 Estrogen Receptor-Positive Breast Cancer

18F-FDG PET和18F-FES PET在分期G1-2雌激素受体阳性乳腺癌中的诊断准确性

RADIOLOGY
IF15.2
2025-03-010
PRE
Intrapatient 16a-[18F]Fluoro-17b-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer

患者体内16a-[18F]氟-17b-雌二醇PET异质性作为雌激素受体阳性转移性乳腺癌患者内分泌治疗反应和生存的预后因素

2025-01-231
PRE
Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative,-Low, and-Positive Metastatic Breast Cancer

在HER2-Negative,低和阳性转移性乳腺癌中通过HER2 PET鉴定的全身HER2异质性

2024-09-052
PRE
Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer
2024-02-142
OAAI
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)
2024-01-0613
OAAI
EO2401 (E) peptide immunotherapy plus nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP): EOADR1-19/SPENCER
2023-10-011
OA